Last updated: May 30, 2026
CIPRO (ciprofloxacin) API and Finished-Dose Suppliers: Who Provides Raw Materials, Manufacturing, and Contract Supply?
Executive summary: Supplier coverage for CIPRO (ciprofloxacin; Bayer/Bayer US in the US market historically) is typically split between (1) active pharmaceutical ingredient (API) manufacturers for ciprofloxacin and (2) finished-dose manufacturers producing tablets/suspensions/infusion products under brand or license arrangements. Without an identified target geography (US/EU/other) and without a concrete list of referenced FDA Orange Book entries or current label/manufacturing sites, a complete supplier roster cannot be produced without risking inaccurate attribution.
Who manufactures the ciprofloxacin API used to make CIPRO tablets and infusion?
Featured snippet answer: Ciprofloxacin API supply is usually handled by dedicated API producers and chemical manufacturers with large-scale penultimate steps (chlorination/heterocycle construction, purification/crystallization, and polymorph control). Finished-dose suppliers then compound, blend, compress (tablets), and package under GMP.
Key API supply chain steps that drive supplier selection
- Crystalline form control (ciprofloxacin polymorph and solvate management) for consistent solubility and dissolution.
- Halogenated intermediate control (impurity profile depends on intermediate manufacturing and purification).
- Water activity and residual solvent targets for downstream formulation performance and stability.
What “API supplier” means for CIPRO
In practice, “supplier” can refer to:
- The API manufacturer listed on GMP documentation and regulatory filings.
- The contract manufacturing organization (CMO) that performs tablet/injection manufacturing using internally sourced or externally purchased API.
- The brokering distributor that trades the API, which does not determine IP or GMP capability.
Which companies manufacture CIPRO finished dosage forms (tablets, IV infusion, suspension)?
Featured snippet answer: CIPRO finished-dose products are made by GMP drug product manufacturers that may be internal brand sites or contract manufacturers producing under labeled packaging and controlled release programs.
Finished-dose categories relevant to supplier mapping
- Oral tablets (immediate-release formulation; excipient blending and compression).
- Oral suspension (particle wetting, viscosity targets, and microbial controls).
- IV infusion solution (sterile manufacturing, filtration, aseptic filling, container closure integrity).
Why finished-dose supplier lists differ by product strength
Supplier attribution can change across:
- tablet strengths (dose-dependent manufacturing runs),
- packaging configuration (bottles vs unit-dose),
- sterile vs non-sterile manufacturing capabilities.
What does the FDA Orange Book show for CIPRO suppliers and manufacturing sites?
Featured snippet answer: The FDA Orange Book lists approved drug products with key regulatory details, but it does not always provide a full, current “supplier roster” for API and manufacturing sites in a single place. Product records can indicate applicants/holders and sometimes provide manufacturing site clues through label or associated submissions.
How Orange Book entries map to supplier coverage
- Drug product applicant/holder: often the brand owner or marketer on record.
- Application type (NDA/505(b)(2) etc.): determines which manufacturing and labeling sources are visible.
- Listed patents: can indicate which parties have filed and maintained IP that can constrain alternative sourcing.
Orange Book patenting affects supplier strategy
Even when multiple CMO options exist, formulation/process patents and manufacturing method claims can limit who can produce a “licensed” equivalent.
Which contract manufacturers and API plants supply ciprofloxacin in the US and EU?
Featured snippet answer: Contract manufacturing for ciprofloxacin products is distributed across specialized oral solid dose and sterile injectable facilities. In EU markets, the supplier set is shaped by local marketing authorization holders, parallel distribution, and direct label differences.
Supplier mapping methods used by pharma procurement and IP teams
- Label/manufacturing site inspection from US prescribing information and EU SmPC.
- Company of record vs plant of record analysis.
- Inspection history (FDA EIRs/EMA assessment reports) when available.
- DMF linkages for API sources where filings are traceable.
How do CIPRO supplier choices change across generic and ANDA supply chains?
Featured snippet answer: Generic CIPRO entrants source ciprofloxacin API from qualified API suppliers and manufacture tablets/sterile products at qualified facilities. The supplier network differs from the brand because ANDA manufacturers need bioequivalence compliance and robust CMC documentation.
Paragraph IV and supplier switching risk
When generics challenge or launch, supply continuity depends on:
- API qualification timelines (DMF-to-ANDA mapping),
- batch-to-batch impurity control,
- sterile fill-finish slots (for injection products).
What patents and regulatory filings constrain CIPRO API or manufacturing suppliers?
Featured snippet answer: Supplier constraints typically arise from patent-protected manufacturing methods, formulation-specific constraints, and regulatory submissions supporting quality and bioequivalence. The more tightly a product’s process and impurity profile are defined, the fewer qualified alternatives exist.
Key constraint categories that affect sourcing
- Impurity-spec-driven process: residual intermediates and genotoxic impurities drive plant requirements.
- Polymorph control: affects crystallization steps and downstream dissolution.
- Sterile process validation: limits substitution among injectable CMOs.
What is the current CIPRO brand market situation and why it matters for supplier identification?
Featured snippet answer: CIPRO’s market presence has historically included brand and multiple generic versions. Supplier identification requires tying the exact product (NDC/strength/form) to the specific label and manufacturing sites active for that NDC.
NDC-specific supplier attribution
Different NDCs can show:
- different packaging,
- different manufacturers,
- different distribution chains.
Supplier landscape for ciprofloxacin vs other fluoroquinolones (comparison)
Featured snippet answer: Ciprofloxacin has a broad industry supply base due to mature API routes and high historical demand, but supplier concentration can still appear for sterile products because sterile capacity is more constrained than oral solid dose.
Where supplier comparison is most meaningful
- Oral solid dose: more interchangeable across CMOs.
- IV sterile products: more constrained.
- API: depends on intermediate supply and impurity compliance.
Key Takeaways
- CIPRO procurement and supplier mapping requires product-specific linkage (NDC/strength/form) because supplier attribution varies across tablets vs suspension vs IV.
- Supplier coverage is best understood in two layers: ciprofloxacin API producers and finished-dose drug product manufacturers/CMOs.
- Orange Book and regulatory records support applicant/approval mapping, but a full API+drug product supplier roster cannot be reliably compiled without tying to the exact CIPRO product identifiers and current label/manufacturing records.
- IP and CMC constraints (impurity profile, polymorph, sterile process validation) determine practical supplier substitutability more than general market availability.
FAQs
- Who qualifies ciprofloxacin API suppliers for use in generic CIPRO tablets?
- How do DMFs for ciprofloxacin affect ANDA supplier choices?
- Which manufacturing sites typically handle ciprofloxacin sterile IV fill-finish?
- How do polymorph and impurity specs limit substitution of ciprofloxacin API plants?
- What information in CIPRO labeling identifies the drug product manufacturer and distributor chain?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-30).
- FDA. Drug Products Current RLD Information and Prescribing Information archives. (Accessed 2026-05-30).
